Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
NCT02419495 · M.D. Anderson Cancer Center · PHASE1 · terminated · last registry update 2025-06-04 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Administratively Complete” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-30Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cisplatin (NCT02486718)
- 2024-10-09Phase 3 first posted: Alliance for Clinical Trials in Oncology, Cisplatin + Carboplatin (NCT06632327)
- 2024-08-26Results posted on the registry: Hoffmann-La Roche, Alectnib + Cisplatin (NCT03456076)
- 2024-08-21Phase 3 first posted: AstraZeneca, Datopotamab Deruxtecan + Rilvegostomig (NCT06564844)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision